News - Abbott Laboratories


Current filters:

Abbott Laboratories

Popular Filters

37 to 61 of 77 results

Added European indications for Abbott's Humira and Novartis' Afinitor


US health care major Abbott Laboratories (NYSE: ABT) today announced that the European Commission (EC)…

Abbott LaboratoriesAfinitorAnti-Arthritics/RheumaticsEuropeHumiraNovartisOncologyPharmaceuticalRegulation

Abbott continues to see earnings growth, beating 2nd-qtr expectations


US health care group Abbott Laboratories (NYSE: ABT), which is scheduled to split into two separate companies,…

Abbott LaboratoriesFinancialPharmaceutical

Five more drug majors join NIH initiative to speed therapeutic discovery


Five additional pharmaceutical companies have joined a US National Institutes of Health-led effort to…

Abbott LaboratoriesBristol-Myers SquibbGlaxoSmithKlineJohnson & JohnsonNorth AmericaPharmaceuticalResearchSanofi

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR


Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

Abbott Labs agrees $1.6 billion settlement over Depakote marketing practices


Ending a four year investigation, US health care major Abbott Laboratories (NYSE: ABT) has reached a…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Abbott Labs acquires drug candidate from Action Pharma


US health care group Abbott Laboratories (NYSE: ABT) and Action Pharma A/S, a privately-owned company…

Abbott LaboratoriesAction PharmaLicensingNephrology and HepatologyPharmaceuticalZealand Pharma

Abbott beats forecasts as 1st-qtr sees strong sales and earnings growth


US health care major Abbott Laboratories (NYSE: ABT) pleased investors yesterday, reporting better-than-expected…

Abbott LaboratoriesFinancialPharmaceutical

Abbott's Humira OKed for new ulcerative colitis indication in EU


Following a previous favorable advisory committee recommendation, US health care major Abbott Laboratories…

Abbott LaboratoriesEuropeGastro-intestinalsHumiraInflammatory diseasesPharmaceuticalRegulation

AbbVie selected as name for Abbott research-based spin out


Confirming its previous announcements on plans to split the US health care major, Abbott Laboratories…

Abbott LaboratoriesAbbVieMergers & AcquisitionsPharmaceutical

Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers


The number of patent applications filed by leading pharmaceutical companies for biological drugs has…

Abbott LaboratoriesBiotechnologyGlaxoSmithKlineNovartisPatentsPfizerPharmaceuticalResearchSanofi

Watson confirms Abbott Niaspan patent challenge


USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

Abbott LaboratoriesCardio-vascularGenericsNiaspanNorth AmericaPatentsWatson Pharmaceuticals

Abbott unit snaps up LIMS distributors


As part of a series of strategic moves to build its laboratory information management system (LIMS) business…

Abbott LaboratoriesMergers & AcquisitionsPharmaceuticalSTARLIMS

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs


Belgian drug developer Galapagos (Euronext: GLPG) saw its shares rocket 27% to a record high 13.89 euros…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGalapagosLicensingPharmaceutical

EMA advisory backs Humira for UC and expanded use of Byetta


The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on Friday…

Abbott LaboratoriesAmylinAnti-Arthritics/RheumaticsBiotechnologyByettaDiabetesEli LillyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Abbott on track to split; posts higher earnings


Despite another challenging year for the global economy, US health care major Abbott (NYSE: ABT) again…

Abbott LaboratoriesFinancialPharmaceutical

Emergent considers options as Abbott ends drug R&D collaboration


Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Abbott in further deal with Reata


US health care major Abbott Laboratories (NYSE: ABT) has entered into a second mega-million dollar licensing…

Abbott LaboratoriesAnti-Arthritics/RheumaticsbardoxoloneBiotechnologyLicensingNeurologicalPharmaceuticalReata Pharmaceuticals

Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine


A global campaign to challenge US health care major Abbott Laboratories’ (NYSE: ABT) monopolistic…

Abbott LaboratoriesAnti-viralsGenericsGlobalKaletra CapsulesPharmaceuticalPricing

Litigation hits Abbott Lab’s 3rd-qtr, but shares leap as firm says it will split in two


US health care major Abbott Laboratories (NYSE: ABT) saw its shares leap 10% in morning trading yesterday,…

Abbott LaboratoriesFinancialPharmaceutical

Abbott and Eisai launch of PDER drug Lipacreon in Japan


Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

US FDA approves Pfizer lung cancer drug Xalkori and companion diagnostic from Abbott


The US Food and Drug Administration has approved global drugs behemoth Pfizer’s (NYSE: PFE) Xalkori…

Abbott LaboratoriescrizotinibNorth AmericaOncologyPfizerPharmaceuticalRegulationXalkori

37 to 61 of 77 results

Back to top